https://news.medxy.ai/zh/cardiac-resynchronization-therapy-in-nonischemic-cardiomyopathy/Medxy AIzh2026-08-07T12:38:38-07:00非缺血性心肌病中CRT是否需要联合除颤器？——基于DECIDE-CRT及相关研究的证据综述与临床启示 https://news.medxy.ai/ja/cardiac-resynchronization-therapy-with-or-without-defibrillator-in-nonischemic-cardiomyopathy/Medxy AIja2026-08-07T12:38:15-07:00非虚血性心筋症におけるCRTは除細動器併用が必要か：DECIDE-CRTと関連研究から読み解くエビデンスと臨床的含意 https://news.medxy.ai/vi/cardiac-resynchronization-therapy-with-or-without-defibrillator-in-nonischemic-cardiomyopathy-evidence-synthesis-and-clinical-implications/Medxy AIvi2026-08-07T12:37:45-07:00Liệu pháp tái đồng bộ tim có hoặc không kèm máy khử rung ở bệnh cơ tim không do thiếu máu cục bộ: Tổng hợp bằng chứng và hàm ý lâm sàng từ DECIDE-CRT và các nghiên cứu liên quan https://news.medxy.ai/cardiac-resynchronization-therapy-with-or-without-defibrillator-in-nonischemic-cardiomyopathy-evidence-synthesis-and-clinical-implications-from-decide-crt-and-related-studies/Medxy AIen2026-08-07T12:36:09-07:00Cardiac Resynchronization Therapy With or Without Defibrillator in Nonischemic Cardiomyopathy: Evidence Synthesis and Clinical Implications from DECIDE-CRT and Related Studies https://news.medxy.ai/zh/u-shaped-between-left-ventricular-and-mortality-in-heart-failure/Medxy AIzh2026-08-07T12:32:53-07:00左心室大小与心力衰竭死亡风险：U型关系的临床启示 https://news.medxy.ai/ja/u-shaped-between-left-ventricular-size-and-mortality-in-heart-failure/Medxy AIja2026-08-07T12:32:35-07:00心不全における左室サイズと死亡率のU字型関係を読み解く https://news.medxy.ai/vi/u-shaped-relationship-between-left-ventricular-size-and-mortality-in-heart-failure/Medxy AIvi2026-08-07T12:32:16-07:00Giải mã mối liên quan hình chữ U giữa kích thước thất trái và tử vong ở bệnh nhân suy tim https://news.medxy.ai/decoding-the-u-shaped-relationship-between-left-ventricular-size-and-mortality-in-heart-failure-patients/Medxy AIen2026-08-07T12:31:15-07:00Decoding the U-Shaped Relationship Between Left Ventricular Size and Mortality in Heart Failure Patients https://news.medxy.ai/zh/combined-transcatheter-mitral-and-tricuspid-edge-to-edge-repair-in-patients-with-moderate-mitral-regurgitation-and-severe-tricuspid-regurgitation/Medxy AIzh2026-08-07T12:07:55-07:00联合经导管二尖瓣与三尖瓣缘对缘修复在中度二尖瓣反流合并重度三尖瓣反流患者中的临床影响 https://news.medxy.ai/impact-of-combined-transcatheter-mitral-and-tricuspid-edge-to-edge-repair-in-patients-with-moderate-mitral-regurgitation-and-severe-tricuspid-regurgitation/Medxy AIen2026-08-07T12:06:02-07:00Impact of Combined Transcatheter Mitral and Tricuspid Edge-to-Edge Repair in Patients with Moderate Mitral Regurgitation and Severe Tricuspid Regurgitation https://news.medxy.ai/zh/7-year-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIzh2026-08-07T12:04:58-07:00TAVR 与 SAVR 在低风险主动脉瓣狭窄患者中的 7 年健康结局：PARTNER 3 试验解读 https://news.medxy.ai/ja/7-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIja2026-08-07T12:04:38-07:00低リスク大動脈弁狭窄症におけるTAVRとSAVRの7年転帰：PARTNER 3試験から得られた知見 https://news.medxy.ai/vi/seven-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients/Medxy AIvi2026-08-07T12:04:18-07:00Sau 7 năm, TAVR và SAVR mang lại kết cục sức khỏe ra sao ở bệnh nhân hẹp động mạch chủ nguy cơ thấp? Dữ liệu từ thử nghiệm PARTNER 3 https://news.medxy.ai/seven-year-health-outcomes-after-tavr-versus-savr-in-low-risk-aortic-stenosis-patients-insights-from-the-partner-3-trial/Medxy AIen2026-08-07T12:03:14-07:00Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 Trial https://news.medxy.ai/zh/lv-hypertrabeculation-in-dilated-cardiomyopathy/Medxy AIzh2026-08-07T12:01:02-07:00扩张型心肌病中的左心室过度肌小梁化：预后提示与临床意义 https://news.medxy.ai/ja/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy/Medxy AIja2026-08-07T12:00:44-07:00拡張型心筋症における左室過剰肉柱形成：予後の見通しと臨床的意義 https://news.medxy.ai/vi/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy-prognostic/Medxy AIvi2026-08-07T12:00:24-07:00Tăng bè thất trái trong bệnh cơ tim giãn: ý nghĩa tiên lượng và hàm ý lâm sàng https://news.medxy.ai/left-ventricular-hypertrabeculation-in-dilated-cardiomyopathy-prognostic-insights-and-clinical-implications/Medxy AIen2026-08-07T11:59:04-07:00Left Ventricular Hypertrabeculation in Dilated Cardiomyopathy: Prognostic Insights and Clinical Implications https://news.medxy.ai/zh/electronic-patient-reported-outcome-with-alert-based-interventions-in-metastatic-breast-cancer-2/Medxy AIzh2026-08-07T11:55:09-07:00转移性乳腺癌的电子患者报告结局监测：警报触发干预的证据与临床启示 https://news.medxy.ai/ja/electronic-patient-reported-outcome-with-alert-based-interventions-in-metastatic-breast-cancer/Medxy AIja2026-08-07T11:54:46-07:00転移性乳がんにおける電子患者報告アウトカムモニタリングとアラート介入：エビデンスと臨床的意義の整理 https://news.medxy.ai/vi/electronic-patient-reported-outcome-monitoring-with-alert-based-interventions-in-metastatic-breast-cancer/Medxy AIvi2026-08-07T11:54:21-07:00Theo dõi kết cục do người bệnh tự báo cáo bằng điện tử trong ung thư vú di căn: bằng chứng và ý nghĩa lâm sàng của can thiệp dựa trên cảnh báo https://news.medxy.ai/electronic-patient-reported-outcome-monitoring-with-alert-based-interventions-in-metastatic-breast-cancer-a-review-of-evidence-and-clinical-implications/Medxy AIen2026-08-07T11:53:17-07:00Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Review of Evidence and Clinical Implications https://news.medxy.ai/zh/enfortumab-vedotin-induced-cutaneous-toxicity-and-survival-in-urothelial-carcinoma/Medxy AIzh2026-08-07T11:49:11-07:00恩福妥珠单抗维多汀相关皮肤毒性：晚期尿路上皮癌生存获益的潜在标志 https://news.medxy.ai/ja/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-survival-in-urothelial-carcinoma/Medxy AIja2026-08-07T11:48:48-07:00エンホルツマブ ベドチンによる皮膚毒性は予後改善のサインか：進行尿路上皮癌における生存との関連 https://news.medxy.ai/vi/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-survival-in-advanced-urothelial-carcinoma/Medxy AIvi2026-08-07T11:48:07-07:00Độc tính da do Enfortumab Vedotin: Dấu ấn gợi ý cải thiện sống còn trong ung thư biểu mô niệu mô tiến triển https://news.medxy.ai/enfortumab-vedotin-induced-cutaneous-toxicity-a-marker-of-improved-survival-in-advanced-urothelial-carcinoma/Medxy AIen2026-08-07T11:47:03-07:00Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma https://news.medxy.ai/zh/antifungal-therapies-for-tinea-capitis/Medxy AIzh2026-08-07T11:46:23-07:00头癣抗真菌治疗效果如何？中国多中心研究给出新线索 https://news.medxy.ai/ja/efficacy-of-antifungal-therapies-for-tinea-capitis/Medxy AIja2026-08-07T11:46:05-07:00頭部白癬に対する抗真菌治療の有効性：中国の多施設研究から見えたこと https://news.medxy.ai/vi/efficacy-of-antifungal-therapies-in-tinea-capitis/Medxy AIvi2026-08-07T11:45:45-07:00Điều trị nấm da đầu: hiệu quả của các thuốc kháng nấm qua nghiên cứu đa trung tâm tại Trung Quốc https://news.medxy.ai/efficacy-of-antifungal-therapies-in-tinea-capitis-insights-from-a-multicenter-study-in-china/Medxy AIen2026-08-07T11:44:32-07:00Efficacy of Antifungal Therapies in Tinea Capitis: Insights from a Multicenter Study in China https://news.medxy.ai/zh/migraine-and-sinus-headaches-in-patients-with-primary-rhinoplasty/Medxy AIzh2026-08-07T11:42:13-07:00初次鼻整形患者中偏头痛与鼻窦性头痛的发生率：临床综述 https://news.medxy.ai/ja/migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty/Medxy AIja2026-08-07T11:41:52-07:00一次鼻形成術における片頭痛・副鼻腔頭痛の頻度：臨床レビュー https://news.medxy.ai/vi/frequency-of-migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty/Medxy AIvi2026-08-07T11:41:28-07:00Đau nửa đầu và đau đầu do xoang ở bệnh nhân phẫu thuật tạo hình mũi nguyên phát: tổng quan lâm sàng https://news.medxy.ai/frequency-of-migraine-and-sinus-headaches-in-patients-undergoing-primary-rhinoplasty-a-clinical-review/Medxy AIen2026-08-07T11:40:24-07:00Frequency of Migraine and Sinus Headaches in Patients Undergoing Primary Rhinoplasty: A Clinical Review https://news.medxy.ai/zh/%e6%8f%90%e5%8d%87%e4%b9%b3%e6%88%bf%e7%9a%ae%e7%93%a3%e5%ad%98%e6%b4%bb%e8%af%84%e4%bc%b0%ef%bc%9a%e6%bf%80%e5%85%89%e6%95%a3%e6%96%91%e5%af%b9%e6%af%94%e6%88%90%e5%83%8f%e4%b8%8e%e5%90%b2%e5%93%9a/Medxy AIzh2026-08-07T11:38:52-07:00提升乳房皮瓣存活评估：激光散斑对比成像与吲哚菁绿荧光谁更优 https://news.medxy.ai/ja/%e4%b9%b3%e6%88%bf%e3%83%95%e3%83%a9%e3%83%83%e3%83%97%e7%94%9f%e5%ad%98%e6%80%a7%e8%a9%95%e4%be%a1%e3%81%ae%e6%96%b0%e5%b1%95%e9%96%8b%ef%bc%9a%e3%83%ac%e3%83%bc%e3%82%b6%e3%83%bc%e3%83%bb%e3%82%b9/Medxy AIja2026-08-07T11:38:21-07:00乳房フラップ生存性評価の新展開：レーザー・スペックル・コントラスト・イメージングとインドシアニングリーン蛍光法の比較 https://news.medxy.ai/vi/nang-cao-danh-gia-kha-nang-song-cua-vat-vu-laser-speckle-contrast-imaging-so-voi-huynh-quang-indocyanine-green/Medxy AIvi2026-08-07T11:38:01-07:00Nâng cao đánh giá khả năng sống của vạt vú: Laser Speckle Contrast Imaging so với huỳnh quang Indocyanine Green https://news.medxy.ai/advancing-breast-flap-viability-assessment-laser-speckle-contrast-imaging-versus-indocyanine-green-fluorescence/Medxy AIen2026-08-07T11:37:15-07:00Advancing Breast Flap Viability Assessment: Laser Speckle Contrast Imaging Versus Indocyanine Green Fluorescence https://news.medxy.ai/zh/higher-education-students-in-england-who-died-by-suspected-suicide-a-national-retrospective-case-series-study/Medxy AIzh2026-08-07T11:35:04-07:00英格兰高等教育学生疑似自杀死亡特征：一项全国性回顾性病例系列研究 https://news.medxy.ai/vi/characteristics-of-higher-education-students-in-england-who-died-by-suspected-suicide/Medxy AIvi2026-08-07T11:34:15-07:00Đặc điểm của sinh viên giáo dục đại học ở Anh tử vong do nghi ngờ tự sát: nghiên cứu chuỗi ca hồi cứu toàn quốc https://news.medxy.ai/characteristics-of-higher-education-students-in-england-who-died-by-suspected-suicide-a-national-retrospective-case-series-study/Medxy AIen2026-08-07T11:32:39-07:00Characteristics of Higher-Education Students in England Who Died by Suspected Suicide: A National Retrospective Case Series Study https://news.medxy.ai/zh/h3-1-nucleosomes-for-renal-replacement-therapy-and-mortality-in-sepsis/Medxy AIzh2026-08-07T11:24:41-07:00H3.1 核小体作为脓毒症肾脏替代治疗与死亡风险预测生物标志物：来自 SISPCT 试验的分析 https://news.medxy.ai/ja/h3-1-nucleosomes-as-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis/Medxy AIja2026-08-07T11:24:06-07:00敗血症の予後予測を担うH3.1ヌクレオソーム：腎代替療法と死亡率を見据えたSISPCT試験解析 https://news.medxy.ai/vi/h3-1-nucleosomes-as-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis-insights-from-the-sispct-trial/Medxy AIvi2026-08-07T11:23:28-07:00Nucleosome H3.1 như dấu ấn sinh học tiên lượng trong điều trị thay thế thận và tử vong ở nhiễm khuẩn huyết: phân tích từ thử nghiệm SISPCT https://news.medxy.ai/h3-1-nucleosomes-as-predictive-biomarkers-for-renal-replacement-therapy-and-mortality-in-sepsis-insights-from-the-sispct-trial/Medxy AIen2026-08-07T11:21:32-07:00H3.1 Nucleosomes as Predictive Biomarkers for Renal Replacement Therapy and Mortality in Sepsis: Insights from the SISPCT Trial https://news.medxy.ai/zh/enhance-trust-empathy-and-comfort-in-serious-illness-communication-4/Medxy AIzh2026-08-07T11:06:57-07:00医生的情绪表达与自我披露：如何在严重疾病沟通中增强信任、同理心与舒适感 https://news.medxy.ai/ja/enhance-trust-empathy-and-comfort-in-serious-illness-communication-3/Medxy AIja2026-08-07T11:06:31-07:00重篤な疾患の対話をより良くするには：医師の感情表出と自己開示が信頼・思いやりに与える好影響 https://news.medxy.ai/vi/enhance-trust-empathy-and-comfort-in-serious-illness-communication-2/Medxy AIvi2026-08-07T11:06:12-07:00Cảm xúc và sự chân thành của bác sĩ trong trao đổi về bệnh nặng: củng cố niềm tin và lòng trắc ẩn https://news.medxy.ai/zh/effectiveness-of-2024-2025-covid19-vaccines-in-adults/Medxy AIzh2026-08-07T11:04:02-07:002024—2025年成人 COVID-19 疫苗有效性估计：近期证据的综合综述 https://news.medxy.ai/ja/effectiveness-of-2024-2025-covid-19-vaccines-in-adults/Medxy AIja2026-08-07T11:03:31-07:00成人における2024～2025年COVID-19ワクチンの有効性推定：最新エビデンスの包括的レビュー https://news.medxy.ai/vi/estimated-effectiveness-of-2024-2025-covid-19-vaccines-in-adults/Medxy AIvi2026-08-07T11:03:08-07:00Hiệu quả của vắc xin COVID-19 2024–2025 ở người lớn: Tổng quan toàn diện về bằng chứng gần đây https://news.medxy.ai/estimated-effectiveness-of-2024-2025-covid-19-vaccines-in-adults-a-comprehensive-review-of-recent-evidence/Medxy AIen2026-08-07T11:00:13-07:00Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults: A Comprehensive Review of Recent Evidence https://news.medxy.ai/ja/acp-2026-position-paper-a-policy-roadmap-to-obesity/Medxy AIja2026-08-07T10:56:17-07:00ACP 2026年声明：肥満予防・治療を「手が届く・受けやすい・スティグマのない」ものにするための政策ロードマップ https://news.medxy.ai/vi/acp-2026-position-paper-a-policy-roadmap-to-obesity-prevention-and-treatment/Medxy AIvi2026-08-07T10:55:37-07:00ACP 2026: Lộ trình chính sách giúp phòng ngừa và điều trị béo phì trở nên dễ tiếp cận, hợp túi tiền và không kỳ thị https://news.medxy.ai/zh/acp-2026-position-paper-a-policy-roadmap-to-make-obesity-prevention-and-treatment/Medxy AIzh2026-08-07T10:54:57-07:00ACP 2026立场文件：让肥胖预防与治疗更可负担、可及并消除污名的政策路线图 https://news.medxy.ai/acp-2026-position-paper-a-policy-roadmap-to-make-obesity-prevention-and-treatment-affordable-accessible-and-stigma-free/Medxy AIen2026-08-07T10:51:17-07:00ACP 2026 Position Paper: A Policy Roadmap to Make Obesity Prevention and Treatment Affordable, Accessible, and Stigma-Free https://news.medxy.ai/zh/advancing-diagnosis-in-myeloproliferative-neoplasms-non-invasive-multiparametric-profiling/Medxy AIzh2026-08-07T10:49:12-07:00破解骨髓增殖性肿瘤诊断难题：ET、前纤维化期与显性骨髓纤维化的非侵入性多参数分型 https://news.medxy.ai/ja/noninvasive-multiparametric-for-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIja2026-08-07T10:48:54-07:00骨髄増殖性腫瘍の診断を前進させる：ET、前線維化期骨髄線維症、顕性骨髄線維症を非侵襲的多項目プロファイリングで読み解く https://news.medxy.ai/vi/non-invasive-multiparametric-for-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIvi2026-08-07T10:48:25-07:00Cải thiện chẩn đoán trong các u tăng sinh tủy: hồ sơ đa thông số không xâm lấn của ET, preMF và PMF xơ hóa rõ https://news.medxy.ai/advancing-diagnosis-in-myeloproliferative-neoplasms-non-invasive-multiparametric-profiling-of-et-premyelo%ef%ac%81brosis-and-overt-myelo%ef%ac%81brosis/Medxy AIen2026-08-07T10:47:13-07:00Advancing Diagnosis in Myeloproliferative Neoplasms: Non-invasive Multiparametric Profiling of ET, Premyelofibrosis, and Overt Myelofibrosis https://news.medxy.ai/zh/swisslegio-score-legionella-in-community-acquired-pneumonia/Medxy AIzh2026-08-07T10:18:26-07:00SwissLEGIO 评分：简化社区获得性肺炎中军团菌检测的实用工具 https://news.medxy.ai/ja/swisslegio-score-legionella-testing-in-community-acquired-pneumonia/Medxy AIja2026-08-07T10:17:53-07:00SwissLEGIOスコア：地域性肺炎におけるレジオネラ検査を効率化する簡便な指標 https://news.medxy.ai/vi/swisslegio-score-streamline-legionella-testing-in-community-acquired-pneumonia/Medxy AIvi2026-08-07T10:17:30-07:00SwissLEGIO: Thang điểm đơn giản hóa giúp tối ưu xét nghiệm Legionella trong viêm phổi mắc phải cộng đồng https://news.medxy.ai/swisslegio-score-a-simplified-tool-to-streamline-legionella-testing-in-community-acquired-pneumonia/Medxy AIen2026-08-07T10:16:23-07:00SwissLEGIO Score: A Simplified Tool to Streamline Legionella Testing in Community-Acquired Pneumonia https://news.medxy.ai/zh/diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-for-acute-appendicitis/Medxy AIzh2026-08-07T09:41:32-07:00急性阑尾炎中 RIPASA 评分与修正 Alvarado 评分谁更准？——来自印度三级中心的比较研究 https://news.medxy.ai/ja/diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-in-acute-appendicitis/Medxy AIja2026-08-07T09:41:14-07:00急性虫垂炎におけるRIPASAスコアと修正Alvaradoスコアの診断精度比較：インド三次医療施設からの知見 https://news.medxy.ai/vi/comparative-diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-in-acute-appendicitis/Medxy AIvi2026-08-07T09:40:54-07:00RIPASA hay Alvarado sửa đổi: thang điểm nào chẩn đoán viêm ruột thừa cấp tốt hơn? https://news.medxy.ai/comparative-diagnostic-accuracy-of-ripasa-and-modified-alvarado-scores-in-acute-appendicitis-insights-from-an-indian-tertiary-centre/Medxy AIen2026-08-07T09:39:25-07:00Comparative Diagnostic Accuracy of RIPASA and Modified Alvarado Scores in Acute Appendicitis: Insights from an Indian Tertiary Centre https://news.medxy.ai/zh/the-race-free-mesa-risk-score/Medxy AIzh2026-08-07T09:12:19-07:00重审心血管风险评估中的种族/族裔变量：无种族/族裔 MESA 风险评分 https://news.medxy.ai/ja/assessment-the-race-free-mesa-risk-score/Medxy AIja2026-08-07T09:12:03-07:00心血管リスク評価における人種・民族の再考：人種を用いないMESAリスクスコア https://news.medxy.ai/vi/race-ethnicity-in-cardiovascular-risk-assessment-the-race-free-mesa-risk-score/Medxy AIvi2026-08-07T09:11:45-07:00Xem xét lại vai trò của chủng tộc/sắc tộc trong đánh giá nguy cơ tim mạch: thang điểm MESA không sử dụng chủng tộc/sắc tộc https://news.medxy.ai/rethinking-race-ethnicity-in-cardiovascular-risk-assessment-the-race-free-mesa-risk-score/Medxy AIen2026-08-07T09:10:24-07:00Rethinking Race/Ethnicity in Cardiovascular Risk Assessment: The Race-Free MESA Risk Score https://news.medxy.ai/zh/lace-and-hospital-scores-for-30-day-readmissions/Medxy AIzh2026-08-07T09:02:20-07:00巴基斯坦三级医院中LACE与HOSPITAL评分预测30天再入院的价值评估 https://news.medxy.ai/ja/evaluating-lace-and-hospital-scores-for-predicting-30-day-readmissions/Medxy AIja2026-08-07T09:02:05-07:00パキスタン三次医療機関における30日再入院予測：LACEスコアとHOSPITAL scoreの有用性を検証 https://news.medxy.ai/vi/enhance-trust-empathy-and-comfort-in-serious-illness-communication/Medxy AIvi2026-08-07T09:01:37-07:00Đánh giá điểm LACE và HOSPITAL trong dự báo tái nhập viện 30 ngày tại bệnh viện tuyến cuối ở Pakistan https://news.medxy.ai/evaluating-lace-and-hospital-scores-for-predicting-30-day-readmissions-in-a-pakistani-tertiary-care-setting/Medxy AIen2026-08-07T08:59:03-07:00Evaluating LACE and HOSPITAL Scores for Predicting 30-day Readmissions in a Pakistani Tertiary Care Setting https://news.medxy.ai/zh/bpnt1-mutations-as-cause-of-vitaminb12-dependent-megaloblastic-anemia/Medxy AIzh2026-08-07T08:58:29-07:00BPNT1 突变：维生素 B12 依赖性巨幼细胞性贫血的新病因 https://news.medxy.ai/ja/bpnt1-mutations-as-cause-of-vitamin-b12-dependent-megaloblastic-anemia/Medxy AIja2026-08-07T08:58:13-07:00BPNT1変異が切り開く、ビタミンB12依存性巨赤芽球性貧血の新規病因 https://news.medxy.ai/vi/bpnt1-mutations-as-a-novel-cause-of-vitamin-b12-dependent-megaloblastic-anemia/Medxy AIvi2026-08-07T08:57:55-07:00Đột biến BPNT1: Nguyên nhân di truyền mới của thiếu máu nguyên hồng cầu khổng lồ phụ thuộc vitamin B12 https://news.medxy.ai/unveiling-bpnt1-mutations-as-a-novel-cause-of-vitamin-b12-dependent-megaloblastic-anemia/Medxy AIen2026-08-07T08:56:18-07:00Unveiling BPNT1 Mutations as a Novel Cause of Vitamin B12-Dependent Megaloblastic Anemia https://news.medxy.ai/zh/surface-topographic-assessment-of-forced-pulmonary-maneuvers-spirometry/Medxy AIzh2026-08-07T08:27:54-07:00无标记表面地形学评估用力呼气动作：在健康受试者中与肺量计的一致性及可靠性 https://news.medxy.ai/ja/surface-topographic-assessment-of-forced-pulmonary-maneuvers-reliability-with-spirometry/Medxy AIja2026-08-07T08:27:29-07:00健常者における努力呼出操作の表面トポグラフィ評価：信頼性とスパイロメトリーとの一致性 https://news.medxy.ai/vi/surface-topographic-assessment-of-forced-pulmonary-maneuvers-reliability-and-agreement-with-spirometry/Medxy AIvi2026-08-07T08:27:07-07:00Đánh giá địa hình bề mặt trong các nghiệm pháp thở gắng sức: Độ tin cậy và mức độ phù hợp với hô hấp ký ở người khỏe mạnh https://news.medxy.ai/surface-topographic-assessment-of-forced-pulmonary-maneuvers-reliability-and-agreement-with-spirometry-in-healthy-participants/Medxy AIen2026-08-07T08:24:47-07:00Surface Topographic Assessment of Forced Pulmonary Maneuvers: Reliability and Agreement with Spirometry in Healthy Participants https://news.medxy.ai/zh/interleukin-6-in-acute-lung-injury-covid19/Medxy AIzh2026-08-06T12:56:07-07:00白细胞介素-6：急性肺损伤与COVID-19治疗获益的关键枢纽 https://news.medxy.ai/ja/interleukin-6-in-acute-lung-injury-covid-19/Medxy AIja2026-08-06T12:55:50-07:00急性肺障害とCOVID-19における治療成功を導く中心因子としてのInterleukin-6 https://news.medxy.ai/vi/interleukin-6-in-acute-lung-injury-and-covid-19/Medxy AIvi2026-08-06T12:55:24-07:00IL-6: mắt xích trung tâm quyết định hiệu quả điều trị trong tổn thương phổi cấp và COVID-19 https://news.medxy.ai/interleukin-6-as-a-central-mediator-of-therapeutic-success-in-acute-lung-injury-and-covid-19/Medxy AIen2026-08-06T12:54:35-07:00Interleukin-6 as a Central Mediator of Therapeutic Success in Acute Lung Injury and COVID-19 https://news.medxy.ai/zh/understanding-and-reducing-diagnostic-delays-in-childhood-uveitis/Medxy AIzh2026-08-06T12:00:29-07:00缩短儿童起病葡萄膜炎的诊断延误：识别并减少确诊迟滞 https://news.medxy.ai/ja/reducing-diagnostic-delays-in-childhood-onset-uveitis/Medxy AIja2026-08-06T12:00:12-07:00小児発症ブドウ膜炎の診断遅延をどう減らすか：その要因と対策を読み解く https://news.medxy.ai/vi/understanding-and-reducing-diagnostic-delays-in-childhood-onset-uveitis/Medxy AIvi2026-08-06T11:59:51-07:00Vượt qua khoảng trễ chẩn đoán: hiểu và giảm trì hoãn trong uveitis khởi phát ở trẻ em https://news.medxy.ai/bridging-the-gap-understanding-and-reducing-diagnostic-delays-in-childhood-onset-uveitis/Medxy AIen2026-08-06T11:59:02-07:00Bridging the Gap: Understanding and Reducing Diagnostic Delays in Childhood Onset Uveitis https://news.medxy.ai/zh/global-axial-length-centile-for-myopia-management-in-children-and-adolescents/Medxy AIzh2026-08-06T11:58:23-07:00全球儿童青少年眼轴长度百分位曲线：近视管理的新参考标准 https://news.medxy.ai/ja/global-axial-length-centile-charts-for-myopia-management-in-children-and-adolescents/Medxy AIja2026-08-06T11:58:08-07:00小児・思春期の近視管理に役立つ新指標：世界規模の眼軸長パーセンタイルチャート https://news.medxy.ai/vi/myopia-management-in-children-and-adolescents/Medxy AIvi2026-08-06T11:57:49-07:00Biểu đồ bách phân vị độ dài trục nhãn cầu toàn cầu: Nguồn tham chiếu mới cho quản lý cận thị ở trẻ em và thanh thiếu niên https://news.medxy.ai/global-axial-length-centile-charts-a-new-reference-for-myopia-management-in-children-and-adolescents/Medxy AIen2026-08-06T11:56:59-07:00Global Axial Length Centile Charts: A New Reference for Myopia Management in Children and Adolescents https://news.medxy.ai/zh/interleukin-6-inhibition-reduce-diabetic-retinopathy-risk/Medxy AIzh2026-08-06T11:48:04-07:00系统性白细胞介素-6抑制：降低糖尿病视网膜病变风险与进展的新策略 https://news.medxy.ai/ja/systemic-interleukin-6-inhibition-reduce-diabetic-retinopathy-risk/Medxy AIja2026-08-06T11:47:46-07:00全身性IL-6阻害は糖尿病網膜症のリスクと進行を抑える新たな治療戦略 https://news.medxy.ai/vi/systemic-interleukin-6-inhibition-reduce-diabetic-retinopathy-risk-and-progression/Medxy AIvi2026-08-06T11:47:27-07:00Ức chế interleukin-6 toàn thân: hướng đi mới đầy hứa hẹn trong giảm nguy cơ và tiến triển bệnh võng mạc đái tháo đường https://news.medxy.ai/systemic-interleukin-6-inhibition-as-a-novel-approach-to-reduce-diabetic-retinopathy-risk-and-progression/Medxy AIen2026-08-06T11:46:40-07:00Systemic Interleukin-6 Inhibition as a Novel Approach to Reduce Diabetic Retinopathy Risk and Progression https://news.medxy.ai/zh/patient-characteristics-on-treatment-choices-in-bilateral-vocal-fold-atrophy/Medxy AIzh2026-08-06T11:23:43-07:00双侧声带萎缩治疗如何选择？一项十年临床数据揭示患者关键特征 https://news.medxy.ai/vi/patient-characteristics-influencing-treatment-choices-in-bilateral-vocal-fold-atrophy/Medxy AIvi2026-08-06T11:23:06-07:00Những yếu tố ở người bệnh chi phối lựa chọn điều trị trong teo hai bên dây thanh: Góc nhìn từ dữ liệu lâm sàng 10 năm https://news.medxy.ai/patient-characteristics-influencing-treatment-choices-in-bilateral-vocal-fold-atrophy-insights-from-a-decade-of-clinical-data/Medxy AIen2026-08-06T11:21:15-07:00Patient Characteristics Influencing Treatment Choices in Bilateral Vocal Fold Atrophy: Insights from a Decade of Clinical Data https://news.medxy.ai/zh/sex-disparities-in-surgical-robot-assisted-surgery/Medxy AIzh2026-08-06T11:12:10-07:00机器人辅助外科早期推广中的手术机会性别差异 https://news.medxy.ai/ja/sex-based-disparities-in-surgical-robot-assisted-surgery/Medxy AIja2026-08-06T11:10:54-07:00ロボット支援手術の導入初期における手術機会の性差 https://news.medxy.ai/vi/sex-based-disparities-in-surgical-opportunities-robot-assisted-surgery/Medxy AIvi2026-08-06T11:09:00-07:00Chênh lệch theo giới trong cơ hội phẫu thuật ở giai đoạn đầu áp dụng phẫu thuật hỗ trợ robot https://news.medxy.ai/sex-based-disparities-in-surgical-opportunities-during-early-adoption-of-robot-assisted-surgery/Medxy AIen2026-08-06T11:07:21-07:00Sex-Based Disparities in Surgical Opportunities During Early Adoption of Robot-Assisted Surgery https://news.medxy.ai/zh/resection-margin-status-in-distal-cholangiocarcinoma-link-recurrence-and-adjuvant-radiotherapy-selection/Medxy AIzh2026-08-06T11:06:43-07:00远端胆管癌切缘状态的预后价值：复发风险与辅助放疗选择 https://news.medxy.ai/ja/resection-margin-status-in-distal-cholangiocarcinoma/Medxy AIja2026-08-06T11:06:06-07:00遠位胆管癌における切除断端状態の意味：再発リスクと術後放射線療法選択への示唆 https://news.medxy.ai/vi/resection-margin-status-in-distal-cholangiocarcinoma-recurrence-and-adjuvant-radiotherapy-selection/Medxy AIvi2026-08-06T11:05:47-07:00Tình trạng bờ cắt sau phẫu thuật ở ung thư đường mật đoạn xa: Ý nghĩa đối với nguy cơ tái phát và lựa chọn xạ trị bổ trợ https://news.medxy.ai/resection-margin-status-in-distal-cholangiocarcinoma-implications-for-recurrence-and-adjuvant-radiotherapy-selection/Medxy AIen2026-08-06T11:04:35-07:00Resection Margin Status in Distal Cholangiocarcinoma: Implications for Recurrence and Adjuvant Radiotherapy Selection https://news.medxy.ai/zh/preoperative-weight-loss-in-obese-women-with-hyperplasia-or-endometrial-cancer/Medxy AIzh2026-08-06T10:35:44-07:00肥胖女性合并非典型增生或低级别子宫内膜癌的术前减重：可行性与结局 https://news.medxy.ai/ja/preoperative-weight-loss-in-obese-women-with-atypical-hyperplasia-or-endometrial-cancer/Medxy AIja2026-08-06T10:35:25-07:00肥満女性の異型過形成・低悪性度子宮内膜癌に対する術前減量：実施可能性と転帰 https://news.medxy.ai/vi/preoperative-weight-loss-in-obese-women-with-atypical-hyperplasia-or-low-grade-endometrial-cancer/Medxy AIvi2026-08-06T10:34:59-07:00Giảm cân trước phẫu thuật ở phụ nữ béo phì mắc tăng sản không điển hình hoặc ung thư nội mạc tử cung độ thấp: Tính khả thi và kết cục https://news.medxy.ai/preoperative-weight-loss-in-obese-women-with-atypical-hyperplasia-or-low-grade-endometrial-cancer-feasibility-and-outcomes/Medxy AIen2026-08-06T10:33:14-07:00Preoperative Weight Loss in Obese Women With Atypical Hyperplasia or Low-Grade Endometrial Cancer: Feasibility and Outcomes https://news.medxy.ai/zh/ultrasound-guided-enucleation-in-robotic-myomectomy/Medxy AIzh2026-08-06T10:29:38-07:00机器人肌瘤剔除术更精准：借助可放入式超声探头实现超声引导下剥除 https://news.medxy.ai/ja/ultrasound-guided-enucleation-using-a-drop-probe-in-robotic-myomectomy/Medxy AIja2026-08-06T10:29:13-07:00ロボット支援下子宮筋腫核出術の精度向上：ドロップイン型プローブを用いた超音波ガイド下核出術 https://news.medxy.ai/vi/ultrasound-guided-enucleation-using-a-drop-in-probe-in-robotic-myomectomy/Medxy AIvi2026-08-06T10:28:56-07:00Nâng cao độ chính xác trong bóc nhân xơ tử cung hỗ trợ bằng robot: bóc tách dưới hướng dẫn siêu âm với đầu dò drop-in https://news.medxy.ai/enhancing-precision-in-robotic-myomectomy-ultrasound-guided-enucleation-using-a-drop-in-probe/Medxy AIen2026-08-06T10:28:08-07:00Enhancing Precision in Robotic Myomectomy: Ultrasound-Guided Enucleation Using a Drop-In Probe https://news.medxy.ai/zh/nonopioid-and-opioid-pain-management-after-laparoscopic-hysterectomy-from-rct/Medxy AIzh2026-08-06T10:27:41-07:00腹腔镜子宫切除术后镇痛：非阿片方案能否替代阿片处方？一项非劣效性随机试验 https://news.medxy.ai/ja/nonopioid-and-opioid-pain-management-after-laparoscopic-hysterectomy-rct/Medxy AIja2026-08-06T10:27:23-07:00腹腔鏡下子宮全摘術後の鎮痛：非オピオイドはオピオイドに劣らないか https://news.medxy.ai/vi/nonopioid-vs-opioid-pain-management-after-laparoscopic-hysterectomy/Medxy AIvi2026-08-06T10:27:06-07:00Giảm đau không opioid hay opioid sau cắt tử cung nội soi: kết quả từ một thử nghiệm ngẫu nhiên không kém hơn https://news.medxy.ai/nonopioid-vs-opioid-pain-management-after-laparoscopic-hysterectomy-a-noninferiority-randomized-trial/Medxy AIen2026-08-06T10:26:12-07:00Nonopioid vs Opioid Pain Management After Laparoscopic Hysterectomy: A Noninferiority Randomized Trial https://news.medxy.ai/zh/pegylated-interferon-after-nucleostide-withdrawal-boosts-hbsag-loss/Medxy AIzh2026-08-06T10:25:15-07:00乙型肝炎治疗新进展：核苷（酸）类似物停药后加用聚乙二醇化干扰素，可提高HBeAg阴性患者HBsAg清除率 https://news.medxy.ai/ja/peg-interferon-after-nucleostide-withdrawal-boosts-hbsag-loss-in-hbeag-negative-patients/Medxy AIja2026-08-06T10:24:58-07:00B型肝炎治療の新展開：ヌクレオシ(t)ド中止後のペグ化インターフェロン併用でHBeAg陰性例のHBs抗原消失が向上 https://news.medxy.ai/vi/pegylated-interferon-after-nucleostide-withdrawal-boosts-hbsag-loss-in-hbeag-negative-patients/Medxy AIvi2026-08-06T10:24:37-07:00Tăng hiệu quả điều trị viêm gan B: pegylated interferon sau ngừng nucleos(t)ide analogue giúp cải thiện mất HBsAg ở bệnh nhân HBeAg âm tính https://news.medxy.ai/enhancing-hepatitis-b-treatment-pegylated-interferon-after-nucleostide-withdrawal-boosts-hbsag-loss-in-hbeag-negative-patients/Medxy AIen2026-08-06T10:23:43-07:00Enhancing Hepatitis B Treatment: Pegylated Interferon After Nucleos(t)ide Withdrawal Boosts HBsAg Loss in HBeAg-Negative Patients https://news.medxy.ai/zh/subtype-specific-enteric-neuronal-activation-in-ibs-linking-faecal-proteases/Medxy AIzh2026-08-06T10:22:42-07:00IBS亚型特异性肠神经元激活：粪便蛋白酶与免疫特征的联系 https://news.medxy.ai/ja/subtype-specific-enteric-neuronal-activation-in-ibs-linking-faecal-proteases-and-immune/Medxy AIja2026-08-06T10:22:24-07:00IBSサブタイプ別の腸管神経活性化：糞便中プロテアーゼと免疫シグネチャーの関連 https://news.medxy.ai/vi/subtype-specific-enteric-neuronal-activation-in-ibs/Medxy AIvi2026-08-06T10:22:05-07:00IBS: Kích hoạt nơron ruột đặc hiệu theo thể bệnh liên quan đến protease và dấu ấn miễn dịch trong phân https://news.medxy.ai/subtype-specific-enteric-neuronal-activation-in-ibs-linking-faecal-proteases-and-immune-signatures/Medxy AIen2026-08-06T10:20:51-07:00Subtype-Specific Enteric Neuronal Activation in IBS: Linking Faecal Proteases and Immune Signatures https://news.medxy.ai/zh/liver-stiffness-measurements-for-primary-sclerosing-cholangitis/Medxy AIzh2026-08-06T10:19:42-07:00Fibroscan®肝脏硬度测量在原发性硬化性胆管炎中的预后价值：来自前瞻性FICUS队列的研究洞见 https://news.medxy.ai/ja/liver-stiffness-measurements-in-primary-sclerosing-cholangitis/Medxy AIja2026-08-06T10:19:27-07:00原発性硬化性胆管炎の予後予測における肝硬度測定の有用性：前向きFICUSコホートからの知見 https://news.medxy.ai/vi/liver-stiffness-measurements-as-prognostic-tools-in-primary-sclerosing-cholangitis/Medxy AIvi2026-08-06T10:19:10-07:00Độ cứng gan như một công cụ tiên lượng trong viêm đường mật xơ hóa tiên phát: phát hiện từ đoàn hệ FICUS tiến cứu https://news.medxy.ai/liver-stiffness-measurements-as-prognostic-tools-in-primary-sclerosing-cholangitis-insights-from-the-prospective-ficus-cohort/Medxy AIen2026-08-06T10:17:42-07:00Liver Stiffness Measurements as Prognostic Tools in Primary Sclerosing Cholangitis: Insights from the Prospective FICUS Cohort https://news.medxy.ai/zh/persistence-of-blood-inflammatory-biomarkers-for-long-term-recurrent-stroke-risk-from-the-oxford-vascular-study/Medxy AIzh2026-08-06T09:51:42-07:00血液炎症标志物持续预测长期卒中复发风险：来自牛津血管研究的启示 https://news.medxy.ai/ja/persistence-of-blood-inflammatory-biomarkers-for-long-term-recurrent-stroke-risk/Medxy AIja2026-08-06T09:51:24-07:00血液炎症バイオマーカーは長期脳卒中再発を予測するのか――Oxford Vascular Studyから見えたこと https://news.medxy.ai/vi/persistence-of-blood-inflammatory-biomarkers-for-long-term-recurrent-stroke-risk-insights-from-the-oxford-vascular-study/Medxy AIvi2026-08-06T09:51:02-07:00Dấu ấn viêm trong máu kéo dài: yếu tố dự báo nguy cơ đột quỵ tái phát lâu dài từ nghiên cứu Oxford Vascular Study https://news.medxy.ai/persistence-of-blood-inflammatory-biomarkers-as-predictors-of-long-term-recurrent-stroke-risk-insights-from-the-oxford-vascular-study/Medxy AIen2026-08-06T09:49:16-07:00Persistence of Blood Inflammatory Biomarkers as Predictors of Long-Term Recurrent Stroke Risk: Insights From the Oxford Vascular Study https://news.medxy.ai/zh/ferritin-and-inflammation-in-isolated-rem-sleep-behavior-disorder/Medxy AIzh2026-08-06T09:48:10-07:00孤立性REM睡眠行为障碍中血清铁蛋白与炎症：纵向队列研究新见 https://news.medxy.ai/ja/serum-ferritin-and-inflammation-in-rem-sleep-behavior-disorder/Medxy AIja2026-08-06T09:47:49-07:00孤発性REM睡眠行動障害における血清フェリチンと炎症：縦断コホート研究からみた新知見 https://news.medxy.ai/vi/serum-ferritin-and-inflammation-in-isolated-rem-sleep-behavior-disorder/Medxy AIvi2026-08-06T09:47:20-07:00Ferritin huyết thanh và viêm trong rối loạn hành vi giấc ngủ REM đơn độc: bằng chứng từ các nghiên cứu đoàn hệ theo dõi dọc https://news.medxy.ai/serum-ferritin-and-inflammation-in-isolated-rem-sleep-behavior-disorder-insights-from-longitudinal-cohort-studies/Medxy AIen2026-08-06T09:45:06-07:00Serum Ferritin and Inflammation in Isolated REM Sleep Behavior Disorder: Insights from Longitudinal Cohort Studies https://news.medxy.ai/zh/automated-speech-in-primary-progressive-aphasia/Medxy AIzh2026-08-06T08:41:12-07:00原发性进行性失语症中的自动语音分析：诊断、解剖与病理新见解 https://news.medxy.ai/ja/automated-speech-analysis-in-primary-progressive-aphasia/Medxy AIja2026-08-06T08:40:53-07:00原発性進行性失語症における自動発話解析：診断・解剖・病理からみた知見 https://news.medxy.ai/vi/automated-speech-analysis-in-primary-progressive-aphasia-diagnostic-anatomical/Medxy AIvi2026-08-06T08:40:31-07:00Phân tích lời nói tự động trong chứng mất ngôn ngữ tiến triển nguyên phát: Những hiểu biết chẩn đoán, giải phẫu và bệnh lý học thần kinh https://news.medxy.ai/automated-speech-analysis-in-primary-progressive-aphasia-diagnostic-anatomical-and-pathological-insights/Medxy AIen2026-08-06T08:37:59-07:00Automated Speech Analysis in Primary Progressive Aphasia: Diagnostic, Anatomical, and Pathological Insights https://news.medxy.ai/zh/survival-and-predictors-in-genetic-frontotemporal-dementia-2/Medxy AIzh2026-08-05T14:15:53-07:00遗传性额颞叶痴呆的生存期与预测因素：一项国际回顾性队列研究的启示 https://news.medxy.ai/ja/survival-and-predictors-in-genetic-frontotemporal-dementia/Medxy AIja2026-08-05T14:15:30-07:00遺伝性前頭側頭型認知症の生存期間と予後因子：国際後ろ向きコホート研究からの知見 https://news.medxy.ai/vi/survival-estimates-and-predictors-in-genetic-frontotemporal-dementia/Medxy AIvi2026-08-05T14:15:06-07:00Ước tính sống còn và các yếu tố dự báo trong sa sút trí tuệ thùy trán-thái dương di truyền: Bằng chứng từ một nghiên cứu đoàn hệ hồi cứu quốc tế https://news.medxy.ai/survival-estimates-and-predictors-in-genetic-frontotemporal-dementia-insights-from-an-international-retrospective-cohort-study/Medxy AIen2026-08-05T14:13:50-07:00Survival Estimates and Predictors in Genetic Frontotemporal Dementia: Insights from an International Retrospective Cohort Study https://news.medxy.ai/zh/maternal-third-trimester-trab-levels-on-neonatal-thyroid-function-and-early-childhood-neurodevelopment/Medxy AIzh2026-08-05T14:07:26-07:00母体妊娠晚期TRAb水平对新生儿甲状腺功能及儿童早期神经发育的影响：来自双向队列研究的启示 https://news.medxy.ai/ja/maternal-third-trimester-trab-levels-on-neonatal-thyroid-function-and-early-childhood-neurodevelopment-insights-from-a-bidirectional-cohort-study/Medxy AIja2026-08-05T14:07:06-07:00妊娠後期の母体TRAb高値は新生児甲状腺機能と乳幼児の神経発達にどう影響するか：双方向コホート研究からの示唆 https://news.medxy.ai/vi/impact-of-maternal-third-trimester-trab-levels-on-neonatal-thyroid-function-and-early-childhood-neurodevelopment-from-a-bidirectional-cohort-study/Medxy AIvi2026-08-05T14:06:43-07:00TRAb của mẹ ở tam cá nguyệt thứ ba ảnh hưởng thế nào đến chức năng tuyến giáp sơ sinh và phát triển thần kinh sớm của trẻ? https://news.medxy.ai/impact-of-maternal-third-trimester-trab-levels-on-neonatal-thyroid-function-and-early-childhood-neurodevelopment-insights-from-a-bidirectional-cohort-study/Medxy AIen2026-08-05T14:05:53-07:00Impact of Maternal Third-Trimester TRAb Levels on Neonatal Thyroid Function and Early Childhood Neurodevelopment: Insights from a Bidirectional Cohort Study https://news.medxy.ai/zh/polygenic-scores-to-predict-diabetes-risk-after-gestational-diabetes-from-a-30-year-cohort-study/Medxy AIzh2026-08-05T13:54:00-07:00借助多基因评分预测妊娠期糖尿病后的糖尿病风险：一项30年队列研究的启示 https://news.medxy.ai/ja/leveraging-polygenic-scores-to-predict-diabetes-risk-after-gestational-diabetes-from-a-30-year-cohort-study/Medxy AIja2026-08-05T13:53:40-07:00妊娠糖尿病後の糖尿病リスク予測におけるpolygenic scoreの活用：30年追跡コホート研究からの知見 https://news.medxy.ai/leveraging-polygenic-scores-to-predict-diabetes-risk-after-gestational-diabetes-insights-from-a-30-year-cohort-study/Medxy AIen2026-08-05T13:52:33-07:00Leveraging Polygenic Scores to Predict Diabetes Risk After Gestational Diabetes: Insights from a 30-Year Cohort Study https://news.medxy.ai/zh/partial-lipodystrophy-cushings-syndrome/Medxy AIzh2026-08-05T13:51:22-07:00部分性脂肪营养不良与库欣综合征如何区分：临床重叠与诊断难点 https://news.medxy.ai/ja/partial-lipodystrophy-from-cushings-syndrome/Medxy AIja2026-08-05T13:51:04-07:00部分性脂肪萎縮症とCushing症候群を見分けるには：臨床像の重なりと診断の難しさ https://news.medxy.ai/vi/distinguishing-partial-lipodystrophy-from-cushings-syndrome/Medxy AIvi2026-08-05T13:50:42-07:00Phân biệt loạn dưỡng mỡ một phần với hội chứng Cushing: những điểm giao thoa lâm sàng và thách thức chẩn đoán https://news.medxy.ai/distinguishing-partial-lipodystrophy-from-cushings-syndrome-clinical-overlaps-and-diagnostic-challenges/Medxy AIen2026-08-05T13:49:39-07:00Distinguishing Partial Lipodystrophy from Cushing’s Syndrome: Clinical Overlaps and Diagnostic Challenges https://news.medxy.ai/zh/prior-authorization-suspension-boosts-to-diabetes-and-improves-glycemic-control-in-populations/Medxy AIzh2026-08-05T13:49:29-07:00暂停事先授权，有助于扩大糖尿病技术可及性并改善弱势人群血糖控制 https://news.medxy.ai/ja/prior-authorization-suspension-boosts-to-diabetes-technology-and-improves-glycemic-control-in-populations/Medxy AIja2026-08-05T13:49:11-07:00事前承認停止で糖尿病テクノロジーへのアクセスが拡大し、医療資源の乏しい集団の血糖管理が改善 https://news.medxy.ai/vi/prior-authorization-suspension-boosts-access-to-diabetes-technology-and-improves-glycemic-control-in-populations/Medxy AIvi2026-08-05T13:48:50-07:00Tạm ngừng phê duyệt trước giúp mở rộng tiếp cận công nghệ đái tháo đường và cải thiện kiểm soát đường huyết ở nhóm dân cư thiếu thụ hưởng https://news.medxy.ai/prior-authorization-suspension-boosts-access-to-diabetes-technology-and-improves-glycemic-control-in-underserved-populations/Medxy AIen2026-08-05T13:48:02-07:00Prior Authorization Suspension Boosts Access to Diabetes Technology and Improves Glycemic Control in Underserved Populations https://news.medxy.ai/zh/donor-heart-preservation-outcomes-with-10c-versus-4-8c-in-adult-heart-transplantation/Medxy AIzh2026-08-05T13:46:42-07:00优化供心保存：成人心脏移植中10°C较4–8°C可获得更优结局 https://news.medxy.ai/ja/donor-heart-preservation-superior-outcomes-with-10c-versus-4-8c-in-adult-heart-transplantation/Medxy AIja2026-08-05T13:46:25-07:00ドナー心保存の最適化：成人心臓移植では4～8°Cより10°Cが優れることを示した研究 https://news.medxy.ai/optimizing-donor-heart-preservation-superior-outcomes-with-10c-versus-4-8c-in-adult-heart-transplantation/Medxy AIen2026-08-05T13:45:18-07:00Optimizing Donor Heart Preservation: Superior Outcomes with 10°C Versus 4-8°C in Adult Heart Transplantation https://news.medxy.ai/ja/womens-heart-centres-esc-consensus-on-sex-sensitive-cardiovascular-care/Medxy AIja2026-08-05T13:06:36-07:00女性の心臓センターをどうつくるか：ESCが示した、性差に配慮した心血管ケアの新たなコンセンサス https://news.medxy.ai/zh/womens-heart-centres-the-esc-consensus-on-sex-sensitive-cardiovascular-care/Medxy AIzh2026-08-05T13:05:25-07:00女性心脏中心：ESC关于组织化、性别敏感心血管照护的共识 https://news.medxy.ai/womens-heart-centres-the-esc-consensus-on-organized-sex-sensitive-cardiovascular-care/Medxy AIen2026-08-05T13:02:08-07:00Women’s Heart Centres: The ESC Consensus on Organized, Sex-Sensitive Cardiovascular Care https://news.medxy.ai/zh/elective-left-ventricular-unloading-in-high-risk-pci-bcis3-substudy/Medxy AIzh2026-08-05T12:51:46-07:00高危PCI中择期左心室卸载的价值：来自CHIP-BCIS3亚组研究的启示 https://news.medxy.ai/ja/elective-left-ventricular-unloading-in-high-risk-pci-chip-bcis3-substudy/Medxy AIja2026-08-05T12:51:31-07:00高リスクPCIにおける待機的左室アンローディングの評価：CHIP-BCIS3サブスタディからの知見 https://news.medxy.ai/vi/evaluating-elective-left-ventricular-unloading-in-high-risk-pci-chip-bcis3-substudy/Medxy AIvi2026-08-05T12:51:12-07:00Đánh giá giảm tải thất trái có chủ đích trong PCI nguy cơ cao: Kết quả từ phân tích phụ CHIP-BCIS3 https://news.medxy.ai/evaluating-elective-left-ventricular-unloading-in-high-risk-pci-insights-from-the-chip-bcis3-substudy/Medxy AIen2026-08-05T12:50:26-07:00Evaluating Elective Left Ventricular Unloading in High-Risk PCI: Insights from the CHIP-BCIS3 Substudy